Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2020 - 2025)

Arcutis Biotherapeutics has reported Cash & Current Investments over the past 6 years, most recently at $221.0 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $221.0 million for Q4 2025, down 3.06% from a year ago — trailing twelve months through Dec 2025 was $221.0 million (down 3.06% YoY), and the annual figure for FY2025 was $221.0 million, down 3.06%.
  • Cash & Current Investments for Q4 2025 was $221.0 million at Arcutis Biotherapeutics, up from $191.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for ARQT hit a ceiling of $477.0 million in Q3 2022 and a floor of $190.8 million in Q2 2025.
  • Median Cash & Current Investments over the past 5 years was $331.5 million (2023), compared with a mean of $317.3 million.
  • Biggest five-year swings in Cash & Current Investments: surged 93.59% in 2021 and later plummeted 52.38% in 2023.
  • Arcutis Biotherapeutics' Cash & Current Investments stood at $387.1 million in 2021, then increased by 5.82% to $409.6 million in 2022, then plummeted by 33.63% to $271.9 million in 2023, then fell by 16.15% to $228.0 million in 2024, then fell by 3.06% to $221.0 million in 2025.
  • The last three reported values for Cash & Current Investments were $221.0 million (Q4 2025), $191.1 million (Q3 2025), and $190.8 million (Q2 2025) per Business Quant data.